Hims & Hers Health (HIMS) stock is sliding in Tuesday’s session following a mixed Q4 earnings report released after the close on Feb. 23. While the company beat EPS estimates handily ($0.08 vs. $0.03 expected), revenue of $617.8M came in slightly below the $619.2M consensus, and Q1 guidance of $600M–$625M badly trailed the $653M analyst estimate. Adding to the pressure, management disclosed meaningful uncertainty around the FDA, HHS, and DOJ’s potential actions on the marketing of compounded GLP-1 products, a core pillar of the company’s growth narrative.

Key Drivers of the HIMS Stock Move
- Main Catalyst: Q4 revenue miss combined with below-consensus Q1 guidance and a warning about regulatory risk on compounded GLP-1 products rattled investors. Management also flagged headwinds from its Super Bowl ad spend and shifts in shipping cadences.
- Bull Case: Subscribers crossed 2.5 million, demonstrating continued platform growth. Full-year 2026 sales guidance of $2.7B–$2.9B brackets the $2.741B consensus, and the EPS beat of 167% shows improving profitability. The $1.15B acquisition of Eucalyptus signals aggressive international expansion into Australia, Japan, the UK, Germany, and Canada.
- Bear Case: The GLP-1 regulatory cloud is the dominant risk. If the FDA, HHS, or DOJ moves to restrict compounded semaglutide marketing, a significant growth engine could stall. Q1 guidance of up to $653M is tracking well below Street expectations, and the company remains on the Top 10 Most Shorted Stocks list.

The setup heading into this earnings reaction is challenging. HIMS entered the print already under sector pressure, with relative performance deteriorating steadily since late 2025. The regulatory language around compounded GLP-1s is the single biggest wildcard: uncertainty here is not priced in with precision, which means the stock could face additional volatility in either direction depending on any FDA communication. Short interest remains elevated, which creates both squeeze potential and downside amplification risk.
HIMS Smart Money Activity
Insider filings show routine stock appreciation right disposals by CFO Oluyemi Okupe earlier in the quarter, totaling roughly $720K. No unusual selling clusters or congressional trades were detected. Institutional positioning remains mixed as investors digest regulatory developments tied to GLP-1 exposure.

HIMS Unusual Options
Options flow turned decidedly mixed following the Eucalyptus announcement and weak guidance. Heavy bullish sweeps hit March $14-$16 calls on February 20, with over $600K in premium paid across multiple strikes. However, substantial bearish positioning emerged in longer-dated contracts, including a $859K purchase of May $55 puts and $343K in June $32 puts on February 20. Post-earnings on February 23, traders deployed synthetic strategies with simultaneous call and put purchases on January 2027 $5 strikes totaling over $1M, suggesting volatility plays rather than directional bets.

HIMS Analyst Focus
Analyst sentiment deteriorated sharply in February. BTIG maintained its buy rating but slashed the price target 29% from $85 to $60 on February 2. Bank of America cut to $21 (February 9) and Citigroup to $16.5 (February 9), both reiterating sell ratings. TD Cowen reduced its hold target from $30 to $20. Evercore initiated coverage with a neutral $33 target in mid-January before the sell-off intensified. The median 2026 price target across recent ratings sits near $26, implying 68% upside from current levels but reflecting deep skepticism about near-term catalysts.

HIMS Seasonality
Based on data since October 2019 (6-7 samples per month), HIMS shows strongest seasonal performance in November (71% positive, +18.9% average) and weakest in August (33% positive, -14.6% average) and October (33% positive, -8.7% average). February historically posts a 71% win rate with +7.1% average gains, though March turns negative (33% positive, -6.2% average). The current February weakness contradicts historical patterns, suggesting fundamental rather than seasonal pressures.

HIMS Relative Performance
HIMS has sharply underperformed healthcare peers in recent weeks following the FDA announcement. After being one of the digital health sector’s breakout winners in 2024, the stock has fallen into the lower decile of relative strength versus sector comparables. The rapid shift from momentum leader to regulatory risk story highlights institutional de-risking tied specifically to compounded GLP-1 exposure rather than broad sector weakness.